Incidence of Parkinson's disease in French women from the E3N cohort study over 27 years of follow-up.
Cohort
Drug claims
Incidence
Medical records
Parkinson’s disease
Women
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
27
11
2021
accepted:
06
02
2022
pubmed:
15
3
2022
medline:
23
6
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
Parkinson's disease (PD) is an uncommon disease with a long prodromal period and higher incidence in men than women. Large cohort studies of women with a long follow-up are needed. Within the E3N French cohort study (98,995 women, 40-65 years at baseline), we identified 3,584 participants who self-reported PD or used anti-parkinsonian drugs over 27 years (1992-2018). We obtained medical records to validate PD diagnosis (definite, probable, possible, no). When medical records were not available, we used a validated algorithm based on drug claims to predict PD status. We retained a PD diagnosis for 1,294 women (medical records, 62%; algorithm, 38%). After exclusion of prevalent/possible cases, cases without age at diagnosis, and women lost to follow-up, our analyses included 98,069 women, of whom 1,200 had incident PD (mean age at diagnosis = 71.8 years; incidence rate = 0.494/1,000 person-years). Age-adjusted incidence rates increased over the six first years of follow-up, possibly due to healthy volunteer bias, and remained stable thereafter, similar to incidence rates in women from Western Europe. Forty three percent of PD cases occurred after 20 years of follow-up (2012-2018). The cumulative incidence of PD from 50 to 90 years was 2.41% (95% confidence interval [CI] = 2.27-2.65). PD incidence was lower in ever than never smokers (hazard ratio = 0.86, 95% CI = 0.76-0.96). In conclusion, we estimated PD incidence rates in French women over a 27-year follow-up, and showed stable incidence between 2002 and 2018. The long follow-up and large sample size make this study a valuable resource to improve our knowledge on PD etiology in women.
Identifiants
pubmed: 35286513
doi: 10.1007/s10654-022-00851-y
pii: 10.1007/s10654-022-00851-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-523Subventions
Organisme : ANR, agence nationale de la recherche
ID : ANR-10-COHO-0006
Organisme : ANR, agence nationale de la recherche
ID : ANR-18-CE36-0006-01
Organisme : Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
ID : N°2102918823
Organisme : Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
ID : 2103236497
Informations de copyright
© 2022. Springer Nature B.V.
Références
GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(17)30299-5 .
Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol. 2010;67(7):798–801. https://doi.org/10.1001/archneurol.2010.135 .
doi: 10.1001/archneurol.2010.135
pubmed: 20625084
Elbaz A. Prodromal symptoms of Parkinson’s disease: Implications for epidemiological studies of disease etiology. Revue neurologique. 2016;172(8–9):503–11. https://doi.org/10.1016/j.neurol.2016.07.001 .
doi: 10.1016/j.neurol.2016.07.001
pubmed: 27503097
Moisan F, Kab S, Mohamed F, et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87(9):952–7. https://doi.org/10.1136/jnnp-2015-312283 .
doi: 10.1136/jnnp-2015-312283
pubmed: 26701996
Lv M, Zhang Y, Chen GC, et al. Reproductive factors and risk of Parkinson’s disease in women: a meta-analysis of observational studies. Behav Brain Res. 2017;335:103–10. https://doi.org/10.1016/j.bbr.2017.07.025 .
doi: 10.1016/j.bbr.2017.07.025
pubmed: 28743601
Palacios N, Fitzgerald KC, Hart JE, et al. Particulate matter and risk of parkinson disease in a large prospective study of women. Environ Health. 2014;13:80. https://doi.org/10.1186/1476-069X-13-80 .
doi: 10.1186/1476-069X-13-80
pubmed: 25294559
pmcid: 4201741
Baldi I, Lebailly P, MohammedBrahim B, et al. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol. 2003;157(5):409–14. https://doi.org/10.1093/aje/kwf216 .
doi: 10.1093/aje/kwf216
pubmed: 12615605
Perez F, Helmer C, Dartigues JF, et al. A 15-year population-based cohort study of the incidence of Parkinson’s disease and dementia with Lewy bodies in an elderly French cohort. J Neurol Neurosurg Psychiatry. 2010;81(7):742–6. https://doi.org/10.1136/jnnp.2009.189142 .
doi: 10.1136/jnnp.2009.189142
pubmed: 19965839
Darweesh SK, Verlinden VJ, Stricker BH, et al. Trajectories of prediagnostic functioning in Parkinson’s disease. Brain. 2017. https://doi.org/10.1093/brain/aww291 .
doi: 10.1093/brain/aww291
pubmed: 28082300
Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30(4):842–7. https://doi.org/10.2337/dc06-2011 .
doi: 10.2337/dc06-2011
pubmed: 17251276
Kyrozis A, Ghika A, Stathopoulos P, et al. Dietary and lifestyle variables in relation to incidence of Parkinson’s disease in Greece. Eur J Epidemiol. 2013;28(1):67–77. https://doi.org/10.1007/s10654-012-9760-0 .
doi: 10.1007/s10654-012-9760-0
pubmed: 23377703
Saaksjarvi K, Knekt P, Mannisto S, et al. Reduced risk of Parkinson’s disease associated with lower body mass index and heavy leisure-time physical activity. Eur J Epidemiol. 2014;29(4):285–92. https://doi.org/10.1007/s10654-014-9887-2 .
doi: 10.1007/s10654-014-9887-2
pubmed: 24633681
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. The Lancet Neurology. 2016;15(12):1257–72. https://doi.org/10.1016/s1474-4422(16)30230-7 .
doi: 10.1016/s1474-4422(16)30230-7
pubmed: 27751556
Foltynie T, Matthews FE, Ishihara L, et al. The frequency and validity of self-reported diagnosis of Parkinson’s Disease in the UK elderly: MRC CFAS cohort. BMC Neurol. 2006;6:29. https://doi.org/10.1186/1471-2377-6-29 .
doi: 10.1186/1471-2377-6-29
pubmed: 16925826
pmcid: 1569859
Clavel-Chapelon F, Group ENS. Cohort Profile: The French E3N Cohort Study. Int J Epidemiol. 2015;44(3):801–9. https://doi.org/10.1093/ije/dyu184 .
doi: 10.1093/ije/dyu184
pubmed: 25212479
Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52(6):1214–20. https://doi.org/10.1212/wnl.52.6.1214 .
doi: 10.1212/wnl.52.6.1214
pubmed: 10214746
Moisan F, Gourlet V, Mazurie JL, et al. Prediction model of Parkinson’s disease based on antiparkinsonian drug claims. Am J Epidemiol. 2011;174(3):354–63. https://doi.org/10.1093/aje/kwr081 .
doi: 10.1093/aje/kwr081
pubmed: 21606234
Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601–9. https://doi.org/10.1161/CIRCULATIONAHA.115.017719 .
doi: 10.1161/CIRCULATIONAHA.115.017719
pubmed: 26858290
pmcid: 4741409
Touraine C, Gerds T, Joly P. (2017) SmoothHazard: An R Package for Fitting Regression Models to Interval-Censored Observations of Illness-Death Models. Journal of Statistical Software. https://doi.org/10.18637/jss.v079.i07 .
Bellou V, Belbasis L, Tzoulaki I, et al. Environmental risk factors and Parkinson’s disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord. 2016;23:1–9. https://doi.org/10.1016/j.parkreldis.2015.12.008 .
doi: 10.1016/j.parkreldis.2015.12.008
pubmed: 26739246
Reedijk M, Huss A, Verheij RA, et al. Parkinson’s disease case ascertainment in prospective cohort studies through combining multiple health information resources. PLoS ONE. 2020;15(7): e0234845. https://doi.org/10.1371/journal.pone.0234845 .
doi: 10.1371/journal.pone.0234845
pubmed: 32609766
pmcid: 7329061
Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–56. https://doi.org/10.1093/aje/kwp107 .
doi: 10.1093/aje/kwp107
pubmed: 19494242
pmcid: 2732996
de Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry. 1997;62(1):10–5. https://doi.org/10.1136/jnnp.62.1.10 .
doi: 10.1136/jnnp.62.1.10
pubmed: 9010393
pmcid: 486688
Macleod AD, Henery R, Nwajiugo PC, et al. Age-related selection bias in Parkinson’s disease research: are we recruiting the right participants? Parkinsonism Relat Disord. 2018;55:128–33. https://doi.org/10.1016/j.parkreldis.2018.05.027 .
doi: 10.1016/j.parkreldis.2018.05.027
pubmed: 29871791
Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet (London, England). 2021;397(10291):2284–303. https://doi.org/10.1016/s0140-6736(21)00218-x .
doi: 10.1016/s0140-6736(21)00218-x
Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002;55(1):25–31. https://doi.org/10.1016/s0895-4356(01)00425-5 .
doi: 10.1016/s0895-4356(01)00425-5
pubmed: 11781119
Licher S, Darweesh SKL, Wolters FJ, et al. Lifetime risk of common neurological diseases in the elderly population. J Neurol Neurosurg Psychiatry. 2019;90(2):148–56. https://doi.org/10.1136/jnnp-2018-318650 .
doi: 10.1136/jnnp-2018-318650
pubmed: 30279211
Savica R, Grossardt BR, Bower JH, et al. Time trends in the incidence of Parkinson disease. JAMA Neurol. 2016;73(8):981–9. https://doi.org/10.1001/jamaneurol.2016.0947 .
doi: 10.1001/jamaneurol.2016.0947
pubmed: 27323276
pmcid: 5004732
Sipila JOT, Kaasinen V. No change in the age-adjusted incidence of Parkinson’s disease in finland for more than 25 years. Mov Disord. 2020;35(11):2116–8. https://doi.org/10.1002/mds.28250 .
doi: 10.1002/mds.28250
pubmed: 32876330
Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169(9):1064–9. https://doi.org/10.1093/aje/kwp033 .
doi: 10.1093/aje/kwp033
pubmed: 19299404
pmcid: 2727240
Bornebroek M, de Lau LM, Haag MD, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology. 2007;28(4):193–6. https://doi.org/10.1159/000108110 .
doi: 10.1159/000108110
pubmed: 17851257
Driver JA, Logroscino G, Lu L, et al. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study. BMJ. 2011. https://doi.org/10.1136/bmj.d198.:d198 .
doi: 10.1136/bmj.d198.:d198
pubmed: 21252104
pmcid: 3023971
Gao X, Cassidy A, Schwarzschild MA, et al. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 2012;78(15):1138–45. https://doi.org/10.1212/WNL.0b013e31824f7fc4 .
doi: 10.1212/WNL.0b013e31824f7fc4
pubmed: 22491871
pmcid: 3320056
Goldman SM, Kamel F, Ross GW, et al. Genetic modification of the association of paraquat and Parkinson’s disease. Mov Disord. 2012;27(13):1652–8. https://doi.org/10.1002/mds.25216 .
doi: 10.1002/mds.25216
pubmed: 23045187
pmcid: 3572192